A Cavopulmonary Assist Device for Long-Term Therapy of Fontan Patients

Andreas Escher, MSc,*† Carsten Strauch, MSc,‡ Emanuel J. Hubmann, MSc,§ Michael Hübler, MD,¶ Dominik Bortis, PhD,§ Bente Thamsen, PhD,† Marc Mueller, PhD,** Ulrich Kertzsch, PhD,* Paul U. Thamsen, PhD,‡ Johann W. Kolar, PhD,§ Daniel Zimpfer, MD,† and Marcus Granegger, PhD*†

Treatment of univentricular hearts remains restricted to palliative surgical corrections (Fontan pathway). The established Fontan circulation lacks a subpulmonary pressure source and is commonly accompanied by progressively declining hemodynamics. A novel cavopulmonary assist device (CPAD) may hold the potential for improved therapeutic management of Fontan patients by chronic restoration of biventricular equivalency. This study aimed at translating clinical objectives toward a functional CPAD with preclinical proof regarding hydraulic performance, hemocompatibility and electric power consumption. A prototype composed of hemocompatible titanium components, ceramic bearings, electric motors, and corresponding drive unit was manufactured for preclinical benchtop analysis: hydraulic performance in general and hemocompatibility characteristics in particular were analyzed in-silico (computational fluid dynamics) and validated in-vitro. The CPAD’s power consumption was recorded across the entire operational range. The CPAD delivered pressure step-ups across a comprehensive operational range (0–10 L/min, 0–50 mm Hg) with electric power consumption below 1.5 W within the main operating range. In-vitro hemolysis experiments (N = 3) indicated a normalized index of hemolysis of 3.8 ± 1.6 mg/100 L during design point operation (2500 rpm, 4 L/min). Preclinical investigations revealed the CPAD’s potential for low traumatic and thrombogenic support of a heterogeneous Fontan population (pediatric and adult) with potentially accompanying secondary disorders (e.g., elevated pulmonary vascular resistance or systemic ventricular insufficiency) at distinct physical activities. The low power consumption implied adequate settings for a small, fully implantable system with transcutaneous energy transfer.

Central Message
A novel cavopulmonary assist device showed little traumatic potential at low power consumption and across a comprehensive clinically relevant range of hemodynamic conditions in Fontan patients.

Perspective Statement
Long-term cavopulmonary support remains in its infancy. This study presents a novel cavopulmonary assist device for chronic support in an inclusive Fontan patient population. In-silico and in-vitro analysis delivered the preclinical proof for a fully implantable, hemocompatible device design. Acute and chronic in-vivo trials are proposed to support laboratory findings.
CONGENITAL — Original Submission

The successful preclinical proof provides the rationale for acute and chronic in-vivo trials aiming at the confirmation of laboratory findings and verification of hemodynamic benefit.

**Semin Thoracic Surg**[1]© 2021 The Author(s), Published by Elsevier Inc. This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/)

**Keywords:** Fontan, Chronic cavopulmonary assist device, Mechanical circulatory support, Rotary blood pump

**INTRODUCTION**

Univentricular hearts (UVHs) account for approximately 10% of all congenital heart defects.[1] The majority of patients with UVH undergo a Fontan type palliation with total cavopulmonary connection (TCPC).[2] Given the absence of a subpulmonary ventricle after TCPC completion, pulmonary perfusion is driven by elevated central venous pressures. This is associated with several long-term complications directly related to chronic venous congestion including lymphatic dysfunction, reduced cardiac output and liver fibrosis.[3–5] These complications ultimately result in a failing Fontan circulation[6,7] that presents a primary source of mortality in patients with UVH.

Currently, cardiac transplantation is the only long-term treatment option for patients with failing Fontan circulation. However, due to the limited availability of donor hearts and the complexity of the procedure,[8] cardiac transplantation remains controversially discussed. Meanwhile, the living Fontan population is predicted to double within the next 20 years,[9] underpinning the medical need for alternative long-term treatment strategies.

Mechanical circulatory support (MCS) in failing Fontan patients is challenging and has only been anecdotally reported,[10–19] with poorer results than in biventricular patients with heart failure.[15] Recent advances in the field led to the introduction of MCS devices that are specifically intended for chronic cavopulmonary support.[5,20] Despite the seminal potential of those concepts, it remains unclear whether they meet the clinical demands to adequately support the heterogeneous Fontan population ranging from pediatric to adult patients with individual pursuits of physical activity and potentially accompanying secondary disorders (e.g., elevated pulmonary vascular resistance (PVR) or systemic ventricular insufficiency).

Within an interdisciplinary initiative to meet the medical need for a durable MCS option accessible to an inclusive Fontan population we recently introduced a cavopulmonary assist device (CPAD) specifically designed to substitute the missing subpulmonary ventricle.[22] The aim of the present study was to translate clinical objectives into a corresponding functional, hemocompatible CPAD with subsequent preclinical evaluation. Focus was laid on clinically relevant aspects including the interaction between the CPAD and the cardiovascular system, hemocompatibility as well as electric power consumption.

**MATERIAL AND METHODS**

**CPAD — Clinical Requirements and Device Design**

**Mechanical Design and Vascular Connection**

Clinical requirements regarding the anatomical compliance of a CPAD include the demand for (1) small-sized conception to prevent squeezing of surrounding sensible structures, (2) high durability for chronic application as well as (3) versatile and stable vascular connection to fit an inclusive range of patients.

Above requirements were translated into the CPAD design (Fig. 1D). Once implanted (Fig. 1A), blood from the inferior vena cava (IVC) and superior vena cava (SVC) is entering the flow chamber (Fig. 1B–C) via two inflow cannulae (Ø11 mm), while being rerouted into the left (LPA) and right pulmonary artery (RPA), respectively, along two outflow cannulae (Ø12 mm). Distal ends of the cannula in- and outlets are spaced by 34 mm and 40 mm, respectively.

Pressure rise is generated by a four-bladed impeller (Ø19 mm, h = 9.5 mm, medical-grade titanium). The impeller is supported within a circular flow chamber (Ø30 mm, h = 19 mm, medical grade titanium) using blood-immersed mechanical ball-cup bearings (ball: ruby, cup: silicon-carbide whiskers reinforced aluminum oxide) (Fig. 1B).

Versatile anastomosis of the CPAD to the patient-specific vasculature is realized with custom-made conical grafts. Designed for a diameter evolving from 20 to 11 mm on the inflow (IVC, SVC), and from 12 to 20 mm on the outflow side (LPA, RPA), respectively (Fig. 1C, bottom), the grafts are to be surgically secured on the respective in- and outflow cannulae. The conical shape permits graft shortening to the required vessel diameter facilitating optimal vascular anastomosis. The grafts were manufactured with a previously developed electro-spinning device[23] (conically shaped rotating collector: 1000 rpm, flow rate: 3.5 mL/h, applied voltage: 20 kV, needle diameter: 0.8 mm, spinning time: 15 minutes). Polyvinylidene fluoride-cotrifluoroethylene (PVDF-TrFE) with a concentration of 20wt% dissolved in N,N-dimethylformamide and acetone (6:4) was used for graft fabrication.

**Hydraulic Design**

The support of a heterogeneous Fontan population with potentially accompanying secondary disorders (e.g., elevated...
PVR or systemic ventricular insufficiency) at distinct physical activities may require diversified magnitudes of flow and cavo-pulmonary pressure rises. Accordingly, clinical requirements for a CPAD include the demand for (1) efficient operation across a broad range of flow \( (Q = 0–10 \text{ L/min}) \) and pressure heads \( (H = 0–50 \text{ mm Hg}) \) to provide freedom for physiologically-controlled support of pediatric and adult patients across all clinically relevant conditions, (2) to increase blood flow with rising venous return, (3) to exhibit low resistance toward venous return in the event of stalled pump condition, (4) to operate at low traumatic and thrombogenic potential and (5) to deliver a homogenous mixture of the
hepatic factor to the left and right lung. Loss of the hepatic factor may lead to the degeneration of the pulmonary vasculature.\textsuperscript{24}

Above demands were accounted for in the hydraulic conception of the CPAD. Based on turbomachinery principles the CPAD was hydraulically designed for a rotational speed \((n)\) of 2500 rpm and flow rates of 4 L/min (design point). An imbalanced inflow ratio \((\text{IR})\) of \(Q_{\text{IVC}}/Q_{\text{SVC}} = 2:1\) was deemed representative for a typical condition in young adolescent Fontan patients.\textsuperscript{25} Gap dimensions \((w = 500 \ \mu\text{m})\) were designed as a trade-off accounting for efficient operation, appropriate motor cooling, prevention of pump occlusion (passage of floating thrombi) and reduction of flow obstruction during dysfunctional condition.

**Actuation Design**

Clinical requirements for the electric actuation of a CPAD include the demand for (1) efficient operation to prevent local blood temperature rises above 2 °C due to motor heat losses (ISO14708-1), (2) low power consumption to enable the integration of transcutaneous energy transfer (TET) technologies, (3) a failsafe design to prevent device dysfunction, and (4) minimal dimensions to fit within the small-sized CPAD.

An electric motor complying with above requirements was previously optimized for its specific application in this CPAD.\textsuperscript{26} To ensure a failsafe design, the motor concept was realized by a redundant axial-flux three-phase synchronous motor configuration with stators in the upper and lower flow chamber casing, respectively, and permanent magnets integrated at the top and bottom of the impeller (Fig. 1B). Motor stators were sealed with epoxide resin, each of which covered with a 3D-printed stator cap prototype (Formlabs, Somerville, MA, USA) (Supplementary Section 1).

**Evaluation of Hydraulic Characteristics, Hemocompatibility and Power Consumption**

**In-Silico Hemocompatibility Prediction**

Compliance of the CPAD with stipulated clinical demands regarding hydraulic performance was verified using computational fluid dynamics (CFD) with the package Star CCM+ (Siemens, Munich, Germany) (Fig. 2A, Supplementary Section 2).

As a measure of hemocompatibility, normalized indices of hemolysis (NIH) were computed\textsuperscript{27} and volume portions exposed to shear stresses above \(9, 50\) and \(150\) Pa, respectively, identified.\textsuperscript{28,29} The corresponding analysis was performed for an IR of 2:1 across the operational range. In addition, a passive scalar transport model was incorporated for virtual pump washout analysis during design point operation. The same routine was followed to evaluate the distribution of the hepatic factor to both the LPA and RPA, respectively, for IR's of 2:1 and 3:1. Blood stagnation was defined for velocities below \(0.1\) m/s\textsuperscript{28,29} thus complementing the washout analysis to predict the thrombotic potential within the pump.

**In-Vitro Hydraulic Characterization and CFD Validation**

For in-vitro validation of CFD data, a hydraulic testbench was recently realized,\textsuperscript{30} specifically tailored to accurately characterize hydraulic performance of the CPAD (Supplementary Section 3). Via 3/8” silicon tubings the CPAD was integrated into the four TCPC-mimicking flow paths of the in-vitro testbench (Fig. 2B). The testbench was filled with blood analog...
Potential flow obstruction imposed by a failing CPAD was furthermore inspected by recording the pressure drop across the pump during stalled pump condition (n = 0 rpm).

**In-Vitro Hemolysis Assessment**

Hemolysis experiments were conducted as previously described, in accordance with ASTM-F1841-97 standards, and with the prototype actuated at design point operation. In each experiment, 600 mL of heparinized bovine blood (15 000 international units (IU) per 5 L) was circulating within the circuit. Sample extraction (2 mL) was performed every 60 minutes.

Upon twofold sample centrifugation at 5600xg during 15 minutes for plasma isolation (Microfuge 22R Centrifuge, Beckman Coulter, Brea, CA, USA) and subsequent dilution of 100 μL of the plasma with 1000 μL of sodium carbonate, plasma-free hemoglobin (fHb) was photometrically determined (Photometer 4040_V5+ Robert Riele GmbH & Co KG, Berlin, Germany).

**Monitoring of Electric Power Consumption**

Compliance with the clinical demand for low electric power consumption was verified by the acquisition of motor input phase-voltage and phase-current (current transducer LA 25-NP/SP9, LEM Europe GmbH, Hessen, Germany). Signals were sampled at 20 kHz across the operational range using a dSPACE MicroLAB Box (dSPACE GmBH, Paderborn, Germany). Mean electric power consumption of the CPAD was computed over periods of 50 s:

$$P_{el,mean} = \sum_{p=1}^{3} \left( \frac{1}{N_t} \sum_{t=0}^{t_{end}} u_{ph}(t) \cdot i_{ph}(t) \right)$$

where \(p\) denotes the phase [-], \(u_{ph}\) the phase-voltage [V], \(i_{ph}\) the phase-current [A], \(N_t\) the number of time steps [-], \(t\) the time [s], \(t_0\) the start and \(t_{end}\) the end time of power recording [s], respectively.

**RESULTS**

**Hydraulic and Hemocompatibility Characteristics**

**In-Silico Hemocompatibility Properties**

CFD data showed the CPAD to operate at hydraulic efficiencies (\(\eta_{hyd}\)) (Supplementary Section 4) above 30% across a broad range (Q = 2–8 L/min). Peak efficiencies were identified around design point operation (\(\eta_{hyd} = 45.79\%) (Fig. 3A).

The numerically predicted NIH increased during low-flow, low-efficiency operation (Q = 1–3 L/min, Fig. 3B). However, peak values remained below 1.43 mg/100 L across the clinically relevant range. Blood volumes exposed to shear stresses above 9, 50 and 150 Pa remained below 10, 0.4 and 0.01% of the priming volume in the CPAD, respectively, with noticeable rise toward increasing flow rates (Fig. 3C).

At design point operation, 90 and 95% of the old blood was washed out within \(t_{90}=0.21\) s (8.7 revolutions) and \(t_{95}=0.26\) s (11 revolutions), respectively (Fig. 4A). Further, blood stagnation with velocities below 0.1 m/s was observed in 1.77% of the entire priming volume.

In the event of imbalanced IR’s, the CPAD delivered well-mixed homogeneous outflow to both LPA (50.2% and 49.6%...
of IVC blood during 2:1 and 3:1 IR condition, respectively) and RPA (49.8% and 50.4% of IVC blood during 2:1 and 3:1 IR condition, respectively) (Fig. 4B).

**In-Vitro Hydraulic Properties and CFD Validation**

Figure 5 depicts the in-vitro pressure-flow relationship of the CPAD, illustrated as mean and standard deviation (SD) among different IR's (1:1, 2:1, 3:1). Error bars indicate marginal deviations in generated pressure heads among different IR's (SD < 1.12 mm Hg).

The CPAD provided support across a broad range with maintained pressure step-up’s at high flow rates (Q > 10 L/min for n > 3200 rpm) and peak pressure heads of 52.68 mm Hg (Q = 0 L/min, n = 3900 rpm).

Pressure losses across the CPAD (light green line, Fig. 5) in case of pump failure (n = 0 rpm, pump stalled) ranged from 0.31 to 6.3 mm Hg with resistances between 0.63 and 3.15 mm Hg/(L/min) (Wood Units) for flows within 1 to 4 L/min.

Hydraulic in-vitro measurements showed good agreement (H: RMSE < 0.92 mm Hg) with pressure-flow characteristics calculated using CFD (black markers, Fig. 5, Supplementary Section 5).

**In-Vitro Hemolysis**

Blood was circulating within the in-vitro mock loop in three distinct experiments (N = 3) of 6 h each (Fig. 6). The experimentally determined NIH revealed a value of 3.8 ± 1.6 mg/100 L, while no signs of any depositions were observed throughout the experiments.

**Electric Power Consumption**

The electric power consumption of the CPAD increased with rotational speeds (Fig. 7). It disclosed monotonic dependence on the flow rate with marginal sensitivity to variations in IR (SD < 0.13 W). During design point operation the CPAD run at 0.83 W while the power consumption remained below 1.5 W within the main operating range. Peak values of 3.24 W were measured during off-design operation (n = 3900 rpm, Q = 8 L/min, H = 18.22 mm Hg).
This study aimed at (1) the translation of key clinical demands for cavopulmonary support toward a functional prototype and (2) the verification of its compliance with clinical demands regarding hydraulic performance, hemocompatibility and electric power consumption.

We delivered the proof-of-feasibility to manufacture the previously proposed novel CPAD in an advanced prototype that meets key demands regarding hemocompatibility, robustness, and vascular connection. Pump components complied with material selections of widespread application in implantable blood pumps with a bearing design that comes with long-term experience in both hemocompatibility and durability given its low wear profile. Previous results pointed toward low-level bearing forces combined with a well-washed bearing configuration, which may mitigate the risk of heat generation and thrombus deposition.

Further, the electrospun grafts provide the potential for versatile, leak-tight and tear-resistant anastomosis of the CPAD to patient-specific vasculatures. In-silico and in-vitro findings revealed the CPAD to operate at low traumatic and thrombogenic potential with little electric power consumption across a comprehensive range of clinically relevant hemodynamic conditions (Fig. 8).

In recent years, the scientific community has witnessed subtle progress in the field of long-term mechanical cavopulmonary support. Rodefeld et al were the first to describe the potential for cavopulmonary support using a double-inlet, double-outlet rotary blood pump (RBP) - a seminal work that...
Preclinical proof of a novel assist device for chronic support in Fontan patients

Figure 8. Preclinical evaluation (in-silico, in-vitro) of the CPAD indicated the potential for low traumatic support at low power consumption and across a broad range of hemodynamic conditions (Q = 0–10 L/min, H = 0–50 mm Hg). CPAD, cavopulmonary assist device; H, pressure head; Q, flow rate. (Color version of figure is available online at http://www.semthorcardiovasc.org).
among CFD and in-vitro data (H: RMSE < 0.92 mm Hg, M: RMSE < 0.04 mNm, Supplementary Section 5) supports validity of the numerical results.

In-silico hemocompatibility findings were complemented by in-vitro hemolysis experiments. Experimentally determined values of NIH were more than an order of magnitude smaller than values presented by Giridharan et al but exceeded levels reported by Cysyk et al by nearly factor 4. Yet, direct comparability with the latter studies is hampered given the consideration of different operating conditions. Nevertheless, combined with the twofold reduction in NIH as compared to the HVAD in design point settings, the current prototype without optimized surface finishing points toward a promising hydraulic design.

Aside above hemocompatibility considerations, the CPAD additionally needs to comply with key safety requirements. On the one hand, the risk of pulmonary arteriovenous malformations is to be minimized. For this purpose, the CPAD promotes equally mixed hepatic flow supply to both LPA and RPA even in the event of imbalanced inflow conditions (IR= 2:1, 3:1). On the other hand, the device implantation in TCPC position and thus in series with the cardiovascular system will render the Fontan circulation inherently reliant on the device. Accordingly, device dysfunction with consequent flow obstruction might lead to detrimental hemodynamic compromise. Hence, low pressure loss across a stalled pump is of utmost importance to prevent ultimate failure of the systemic venous circulation in case of device dysfunction.

To this end Rodefeld et al realized a CPAD with a motor stator in the hub and rotor magnets in the impeller, permitting a housing devoid of any geometrically constraining motor stators. Consequently, this enabled wide flow passage between the impeller and housing with marginal flow obstruction (2.8 mm Hg at 3.9 L/min) in case of device failure. However, such design approaches may be constrained by inefficient operation. Consequently, diversified support including increased pressure step-ups may require high impeller speeds accompanied by raised electric power consumption.

Thus, we realized a CPAD that accounts for a trade-off between efficient, low-traumatic broad-range operation in functional state and low obstructive behavior in the event of pump malfunction (flow resistance: 0.63–3.15 mm Hg/(L/min) (Wood Units)). Yet, it remains to be addressed, whether such flow resistance is acceptably tolerated by the patient in case of device dysfunction.

To mitigate the risk of flow obstruction due to device dysfunction, we focused on a failsafe motor conception by redundant dual motor configuration. In addition, the experience with the HM3 may indicate device malfunction (1.6% at 2 years) and pump thrombosis (<0.01 events per patient-year) to be considered a rare event in RBPs with similar design characteristics. Thus, features that may contribute to this excellent failure rate and outcomes of the HM3 are integrated in the proposed CPAD. This contrasts with other devices presented for the same application that incorporate tiny clearance gaps.

Given the large gap dimensions within the CPAD, efforts were taken to optimize the size and efficiency of the electric motors. Around its clinically most relevant operating points, the electric power expenditure of the CPAD (<1.5 W) was substantially below values reported for contemporary MCS devices and the long-term cavopulmonary support systems introduced above. Further, the monotonic relationship between power consumption and pump flow with discernible dependence on imbalanced IR’s revealed the potential for robust and reliable pump flow estimation based on intrinsic pump parameters even in light of varying IR’s. Omitting the need for additional sensors, such neat approaches could create new avenues for informed monitoring of the cardiovascular system’s state in response to device support.

The integration of TET technologies requires the CPAD to accommodate an internal TET component whose implantable battery size proportionally scales with the pump’s power demand. Thus, considering a usable volumetric energy density of 0.125 Wh/mL, the herein presented low electric power consumption may permit the heart size to be reduced by approximately 70% compared to equivalent application in current LVADs which run at higher power expenditures. Hence, the design of a fully implantable system with TET technologies seems promising and may substantially facilitate long-term support of Fontan patients at high patient mobility with eliminated risk for driveline associated adverse events.

Limitations
Except for the in-silico analysis of the IVC/SVC mixing behavior during IR’s of 2:1 and 3:1, respectively, the numerical simulations presented herein are limited to the representative consideration of a typical IR of 2:1.

Further, the reliable numerical estimation of NIH across the operational range is hampered by substantial discrepancies in magnitudes among in-silico and in-vitro data. This constitutes the well-known limitation of current in-silico hemolysis predictions being constrained to comparative evaluations, while failing to replicate absolute measures. Further, direct comparison of NIH computations with in-vitro measurements is hindered given the assumption of smooth surfaces in the simulation setup as opposed to the surfaces in the current prototype that lacks optimal surface finish.

Device implantability was yet solely investigated in a virtual fitting study of a 11-year-old patient. Feasibility to implant the herein presented device in a heterogeneous Fontan population remains to be confirmed in a larger virtual fitting study that also accounts for younger patients with strongly limited anatomical space.

CONCLUSION
Given the inclusive operational range, the promising hemocompatibility properties and the low electric power
consumption the proposed cavopulmonary assist may offer a promising option for the long-term therapy of Fontan patients. These findings underpin the rational for further development by means of acute and chronic in-vivo investigations to confirm hemodynamic benefit in chronic disease associated with the Fontan circulation.

Acknowledgments

The work was supported by the North-German Supercomputing Alliance (HLRN). The computational results presented have been achieved in part using the Vienna Scientific Cluster (VSC). This study was supported by the GIGAX Foundation.

SUPPLEMENTARY MATERIAL

Scanning this QR code will take you to the article title page to access supplementary information.

REFERENCES


